Nasal cavity spraying inactivated influenza virus vaccine and its prepn process

A technology of influenza virus and inactivated vaccine, which can be used in antiviral agents, pharmaceutical formulations, aerosol delivery, etc., and can solve problems such as unreported

Inactive Publication Date: 2006-08-02
侯云德
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0022] The prescription of this influenza virus inactiva

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nasal cavity spraying inactivated influenza virus vaccine and its prepn process
  • Nasal cavity spraying inactivated influenza virus vaccine and its prepn process
  • Nasal cavity spraying inactivated influenza virus vaccine and its prepn process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Take 10,000 units of human recombinant interleukin 2, which was donated by Beijing Yuance Pharmaceutical Co., Ltd.; 1% chitosan was purchased from Sigma Company in the United States, with a molecular weight of 150kD and a deacetylation of more than 85%. The liquid is a phosphoric acid solution containing 1% benzyl alcohol, 1% mannitol, and 0.05% human serum albumin by weight, and its pH value is 7.0;

[0083] After the above three are mixed, mix with the trivalent split influenza virus hemagglutinin antigen (purchased from the Pasteur Institute) according to the volume ratio of 1:1 to prepare the trivalent split influenza virus inactivated vaccine nasal spray, each volume 100 μl for nasal immunization.

Embodiment 2

[0085] Apply the popular influenza virus strains recommended by WHO: H3N2 influenza A virus, H1N1 influenza A virus and influenza B virus. The three viruses were inoculated into the allantois of 9-11-day-old chicken embryos respectively, and after culturing at 37C for 48 hours, respectively Collect the allantoic fluid, use formalin to inactivate the virus, use SDS influenza virus lysing agent to lyse the virus particles, and then separate and purify respectively to obtain the lysed virus;

[0086] Will 5*10 5 A unit of human interferon α2b, 5g of starch was added to 500mL of phosphate buffer solution with a pH of 7.0, and the phosphate buffer solution contained 1g of human serum albumin, 1g of benzyl alcohol, and 5g of mannitol;

[0087] Get 500g split virus, add above-mentioned buffer solution, make trivalent split influenza virus inactivated vaccine nasal cavity spray, dose, be used for nasal cavity immunization.

Embodiment 3

[0089] Apply the influenza virus strains popular in the year recommended by WHO: H3N2 influenza A virus, H1N1 influenza A virus and influenza B virus. The three viruses were inoculated into the allantois of 9-11-day-old chicken embryos respectively. After culturing at 37C for 48 hours, Collect the allantoic fluid respectively, extract the virus hemagglutinin (HA) of three strains of viruses respectively;

[0090] take 10 4 Unit human recombinant interleukin 2 (gifted by Beijing Yuance Pharmaceutical Co., Ltd.), 10g of chitin was added to 500mL of phosphate buffer solution with a pH of 7.0, and the phosphate buffer solution contained 0.6g of human serum albumin, 5g of benzyl alcohol, 0.5 g mannitol;

[0091] Get 500g split virus, add above-mentioned buffer solution, make trivalent split influenza virus inactivated vaccine nasal cavity spray, dose, be used for nasal cavity immunization.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The nasal cavity spraying inactivated influenza virus vaccine contains the following components: cell immunizing factor, natural polysaccharide and influenza virus antigen. The effective synergistic reaction of IL-2 and natural polysaccharide raises the permeating of the influenza virus antigen in nasal cavity, avoids the degradation of enzyme on the antigen and raises the effectiveness of the medicine obviously. It is revealed that the vaccine composing scheme may be well applied in inoculating macro biomolecule to nasal cavity to produce excellent protection effect while stimulating body to generate local immunity reaction and systemic immunity reaction.

Description

Technical field: [0001] The invention relates to a nasal spray type influenza virus inactivated vaccine and a preparation method thereof, belonging to the field of pharmaceutical preparations. Background technique: [0002] Influenza (influenza) has the characteristics of sudden occurrence and rapid spread. It can be popular in small areas or spread all over the world. It is easy to cause complications and cause death in severe cases, which is very harmful. Immunization is an effective way to prevent influenza, and the prevention of influenza has always been a global public health problem. The application of influenza vaccine for immunization prevention has received more and more attention. [0003] There have been three influenza pandemics in the world in the last century: the Spanish flu in 1918-1919; the Asian flu in 1957; and the Hong Kong flu in 1968. The Spanish flu epidemic of 1918-1919 killed about 50 million people in just 11 months. Currently, the World Health Or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/145A61K9/12A61K9/72A61P31/16
Inventor 侯云德赵静马学军段招军张丽兰
Owner 侯云德
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap